Team:Slovenia
From 2008.igem.org
(Difference between revisions)
(9 intermediate revisions not shown) | |||
Line 160: | Line 160: | ||
###################################################### | ###################################################### | ||
--> | --> | ||
- | + | <html><center> | |
+ | <font size="8" color="#C73E4A"><i>Immunobricks</i></font><br> | ||
+ | <br> | ||
+ | </center></html> | ||
---- | ---- | ||
- | + | ||
- | + | ||
- | + | ||
- | < | + | <html> |
- | + | ||
- | + | ||
- | + | ||
</div></center> | </div></center> | ||
<table> | <table> | ||
<tr > | <tr > | ||
- | <td bgcolor="# | + | <td bgcolor="#e3efe7" align="justify" > |
<strong>Abstract for non-specialists</strong><br /><br /> | <strong>Abstract for non-specialists</strong><br /><br /> | ||
<div style="text-align:justify;">Bacteria <i><b>Helicobacter pylori</b></i> infects half of the world population causing gastritis and contributing to increased incidence of ulcers and gastric malignancies. This infection can be treated with multi-drug regime, but this is often associated with induced antibiotic resistance and does not protect individuals from re-infections. Vaccination against <i>H. pylori</i> can therefore be a viable alternative to control this widespread infection. However, developing an effective vaccine against <i>H. pylori</i> has presented a challenge because <i>H. pylori</i> or its components, which have frequently been used as parts of vaccines, are modified by bacteria such that they evade host defense mechanisms. Using synthetic biology approaches we managed to assemble functional <b>“immunobricks”</b> into a <b>designer vaccine</b> with a goal to activate both innate and acquired immune response to <i>H. pylori</i>. We successfully developed two forms of such designer vaccines. One was based on modifying <i>H. pylori</i> component (flagellin) such that it can now be recognized by the immune system. The other relied upon linking <i>H. pylori</i> components to certain molecules of the innate immune response (so called Toll-like receptors) to activate and guide <i>H. pylori</i> proteins to relevant compartments within the immune cell causing optimal innate and acquired immune response. Both types of vaccines have been thoroughly characterized in vitro (in test tubes or cells) as well as in vivo (laboratory mice) exhibiting substantial antibody response. Our strategy of both vaccines’ design is not limited to <i>H. pylori</i> and can be applied to other pathogens. Additionally, our vaccines can be delivered using simple and inexpensive vaccination routes, which could be suitable also in third world countries.</div> | <div style="text-align:justify;">Bacteria <i><b>Helicobacter pylori</b></i> infects half of the world population causing gastritis and contributing to increased incidence of ulcers and gastric malignancies. This infection can be treated with multi-drug regime, but this is often associated with induced antibiotic resistance and does not protect individuals from re-infections. Vaccination against <i>H. pylori</i> can therefore be a viable alternative to control this widespread infection. However, developing an effective vaccine against <i>H. pylori</i> has presented a challenge because <i>H. pylori</i> or its components, which have frequently been used as parts of vaccines, are modified by bacteria such that they evade host defense mechanisms. Using synthetic biology approaches we managed to assemble functional <b>“immunobricks”</b> into a <b>designer vaccine</b> with a goal to activate both innate and acquired immune response to <i>H. pylori</i>. We successfully developed two forms of such designer vaccines. One was based on modifying <i>H. pylori</i> component (flagellin) such that it can now be recognized by the immune system. The other relied upon linking <i>H. pylori</i> components to certain molecules of the innate immune response (so called Toll-like receptors) to activate and guide <i>H. pylori</i> proteins to relevant compartments within the immune cell causing optimal innate and acquired immune response. Both types of vaccines have been thoroughly characterized in vitro (in test tubes or cells) as well as in vivo (laboratory mice) exhibiting substantial antibody response. Our strategy of both vaccines’ design is not limited to <i>H. pylori</i> and can be applied to other pathogens. Additionally, our vaccines can be delivered using simple and inexpensive vaccination routes, which could be suitable also in third world countries.</div> | ||
Line 181: | Line 183: | ||
<tr><td> </td></tr> | <tr><td> </td></tr> | ||
<tr> | <tr> | ||
- | <td bgcolor="# | + | <td bgcolor="#cbcdcb" align="justify"> |
<strong>Scientific abstract</strong><br /> | <strong>Scientific abstract</strong><br /> | ||
<br /> | <br /> | ||
Line 199: | Line 201: | ||
<html><center><img src="https://static.igem.org/mediawiki/2008/0/0e/ImplementationOfChimericFlagell.gif" width="800" height="597" border="0" /></center></html> | <html><center><img src="https://static.igem.org/mediawiki/2008/0/0e/ImplementationOfChimericFlagell.gif" width="800" height="597" border="0" /></center></html> | ||
- | |||
- | |||
<html><center> | <html><center> | ||
- | Experimental work on this project was performed by seven undergraduate students between june and october 2008, supported by their mentors.</center></html> | + | Experimental work on this project was performed by seven undergraduate students between june and october 2008, supported by their mentors.</center> |
+ | </html> | ||
+ | |||
+ | |||
---- | ---- | ||
+ | <html><center> <a href="http://www.ki.si/raziskovalne-enote/l12-laboratorij-za-biotehnologijo/"><font="24"> Department of Biotechnology | ||
+ | <br>National Institute of Chemistry, Slovenia </a> | ||
+ | |||
+ | </html> | ||
+ | |||
<html> | <html> | ||
</p> | </p> | ||
Line 211: | Line 219: | ||
<tr> | <tr> | ||
<td align="center"> | <td align="center"> | ||
- | + | <br /><br /> | |
<a href="http://www4.clustrmaps.com/counter/maps.php?url=https://2008.igem.org/Team:Slovenia" id="clustrMapsLink"><img src="http://www4.clustrmaps.com/counter/index2.php?url=https://2008.igem.org/Team:Slovenia" style="border:0px;" alt="Locations of visitors to this page" title="Locations of visitors to this page" id="clustrMapsImg" onerror="this.onerror=null; this.src='http://www2.clustrmaps.com/images/clustrmaps-back-soon.jpg'; document.getElementById('clustrMapsLink').href='http://www2.clustrmaps.com';" /> | <a href="http://www4.clustrmaps.com/counter/maps.php?url=https://2008.igem.org/Team:Slovenia" id="clustrMapsLink"><img src="http://www4.clustrmaps.com/counter/index2.php?url=https://2008.igem.org/Team:Slovenia" style="border:0px;" alt="Locations of visitors to this page" title="Locations of visitors to this page" id="clustrMapsImg" onerror="this.onerror=null; this.src='http://www2.clustrmaps.com/images/clustrmaps-back-soon.jpg'; document.getElementById('clustrMapsLink').href='http://www2.clustrmaps.com';" /> | ||
</a> | </a> |
Latest revision as of 15:01, 12 December 2008
|
|||
| |||
|
|||
![]()
National Institute of Chemistry, Slovenia
|
|||
|